The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement
Raymond Comenzo
• 1 Jun 2020
Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, explores the results of a study evaluating concurrent dual monoclonal antibody treatment with daratumumab and NEOD001, an anti-amyloid antibody, in systemic amyloid light-chain (AL) amyloidosis with cardiac involvement. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).
